GlaxoSmithKline’s vaccines unit has been a bright spot for the company amid challenges elsewhere, but its recent performance doesn’t make it immune to staff cuts.
GSK is starting a two-year restructuring program at its Belgian vaccine group that’ll reduce its headcount by up to 720 positions, according to the translation of a Wednesday release (PDF). The restructuring will affect R&D, manufacturing and global support functions, and most of the employees who will be affected are managers. Further, GSK doesn’t intend to renew 215 temporary contracts. […]
https://www.fiercepharma.com/vaccines/gsk-cutting-up-to-720-jobs-r-d-manufacturing-and-support-functions-at-massive-belgian